2024 -
CARMENITA: A RANDOMIZED PHASE 2 STUDY OF THE EFFICACY AND SAFETY OF CYTOREDUCTIVE NEPHRECTOMY FOLLOWED BY IMMUNOTARGETED THERAPY OR ONLY IMMUNOTARGETED THERAPY IN PATIENTS WITH METASTATIC CLEAR-CELL RENAL CELL CARCINOMA AND PRIMARY TUMOR IN SITU
Seeking funding